Department of Neurosurgery, Tianjin Medical University General Hospital, Laboratory of Neuro-Oncology, Tianjin Neurological Institute, Key Laboratory of Post-trauma Neuro-repair and Regeneration in Central Nervous System, Ministry of Education, Tianjin Key Laboratory of Injuries, Variations and Regeneration of Nervous System, Tianjin, China; Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; Chinese Glioma Cooperative Group (CGCG), China.
Department of Neurosurgery, Tianjin Medical University General Hospital, Laboratory of Neuro-Oncology, Tianjin Neurological Institute, Key Laboratory of Post-trauma Neuro-repair and Regeneration in Central Nervous System, Ministry of Education, Tianjin Key Laboratory of Injuries, Variations and Regeneration of Nervous System, Tianjin, China; Chinese Glioma Cooperative Group (CGCG), China.
Cancer Lett. 2015 Jan 28;356(2 Pt B):929-36. doi: 10.1016/j.canlet.2014.11.003. Epub 2014 Nov 11.
The identification of single or less genes based on mRNA expression as clinical diagnostic markers for glioblastoma (GBM) remains a challenge. Recent data have shown the potential oncogenic role and prognostic significance of EZH2 in several human cancers. However, the clinical signature and further mechanisms of EZH2 function in gliomagenesis are still poorly understood. In this study, we found that increased EZH2 expression was associated with tumor grade. High expression of EZH2 in GBM was determined to be a strong and independent predictor of short overall survival. Further, we screened EZH2 targets and associated genes in GBM. Repression of EZH2 induced cell cycle arrest and inhibited tumor growth in vivo. This event represents a positive feedback loop with β-catenin/TCF4 and STAT3 signaling. Taken together, EZH2 could be an independent prognostic factor and potential therapeutic target for GBM.
基于 mRNA 表达鉴定单个或少数基因作为胶质母细胞瘤 (GBM) 的临床诊断标志物仍然是一个挑战。最近的数据表明，EZH2 在几种人类癌症中具有潜在的致癌作用和预后意义。然而，EZH2 在胶质瘤发生中的临床特征和进一步的作用机制仍知之甚少。在这项研究中，我们发现 EZH2 表达的增加与肿瘤分级有关。GBM 中 EZH2 的高表达被确定为总生存期短的强烈和独立预测因子。此外，我们在 GBM 中筛选了 EZH2 的靶标和相关基因。EZH2 的抑制诱导细胞周期停滞并抑制体内肿瘤生长。这一事件代表了与β-catenin/TCF4 和 STAT3 信号的正反馈回路。总之，EZH2 可能是 GBM 的一个独立预后因素和潜在的治疗靶点。
